You are here

  • Home
  • Archive
  • Volume 10, Issue 4
  • Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

 

Online download statistics by month:

Online download statistics by month: April 2022 to July 2025

AbstractFullPdf
Apr 202218881946683
May 2022694712220
Jun 202238939198
Jul 202219219342
Aug 202219519848
Sep 202219920065
Oct 202218819372
Nov 202214614762
Dec 202230530665
Jan 202316616760
Feb 202313413764
Mar 202311111463
Apr 2023808251
May 202310010458
Jun 2023606131
Jul 2023606532
Aug 2023737439
Sep 2023858547
Oct 2023818133
Nov 2023818132
Dec 2023838352
Jan 2024707148
Feb 2024929231
Mar 202410610660
Apr 2024959541
May 2024989950
Jun 2024777660
Jul 202411011243
Aug 2024636531
Sep 2024646446
Oct 2024666734
Nov 2024636547
Dec 202413013573
Jan 202510910969
Feb 202515015163
Mar 202510810857
Apr 2025929239
May 202510210462
Jun 2025515120
Jul 2025110
Total695770832791